Drug Trial Radar · NCT05273749
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia
Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
457
Actual
Start
Apr 6, 2022
Primary completion
Nov 14, 2023
Study completion Nov 14, 2023
Sponsor
- Lead sponsor
- Tonix Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of fibromyalgia.
Conditions
- Fibromyalgia
Interventions
TNX-102 SL Tablet, 5.6 mgDrug
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Placebo SL TabletDrug
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to the Week 14 Endpoint in the Diary NRS Weekly Average of Daily Self Reported Average Pain Severity Scores.Time frame: Baseline (Day -7 to Day -1), Week 14
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
Tonix Clinical Site
Phoenix, Arizona
Tonix Clinical Site
Oceanside, California
Tonix Clinical Site
Santa Ana, California
Tonix Clinical Site
Temecula, California
Tonix Clinical Site
Cromwell, Connecticut
Tonix Clinical Site
Fort Myers, Florida
Tonix Clinical Site
Jacksonville, Florida
Tonix Clinical Site
Miami Lakes, Florida
Tonix Clinical Site
Ocala, Florida
Tonix Clinical Site
Oldsmar, Florida
Tonix Clinical Site
Orlando, Florida
Tonix Clinical Site
Alpharetta, Georgia
Tonix Clinical Site
Atlanta, Georgia
Tonix Clinical Site
Evansville, Indiana
Tonix Clinical Site
West Des Moines, Iowa
Tonix Clinical Site
Prairie Village, Kansas
Tonix Clinical Site
Covington, Louisiana
Tonix Clinical Site
New Orleans, Louisiana
Tonix Clinical Site
Prairieville, Louisiana
Tonix Clinical Site
Boston, Massachusetts
Tonix Clinical Site
Gulfport, Mississippi
Tonix Clinical Site
Albuquerque, New Mexico
Tonix Clinical Site
Williamsville, New York
Tonix Clinical Site
Cincinnati, Ohio
Tonix Clinical Site
Tulsa, Oklahoma
Tonix Clinical Site
Portland, Oregon
Tonix Clinical Site
Charleston, South Carolina
Tonix Clinical Site
Austin, Texas
Tonix Clinical Site
Dallas, Texas
Tonix Clinical Site
McKinney, Texas
Tonix Clinical Site
Charlottesville, Virginia
Tonix Clinical Site
Danville, Virginia
Tonix Clinical Site
Kenosha, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.